Companion Diagnostics Market by Technology Type (Immunohistochemistry, Polymerase Chain Reaction [PCR], Next Generation Sequencing [NGS], In Situ Hybridization, and Others), and Indication (Oncology, Neurology, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3250643
- 199 Pages
- July 2019
- Healthcare
Companion diagnostic is a medical device, often an in-vitro device that provides information essential for the safe and effective use of a corresponding drug or biological product. These tests help a health care professional to determine patients who can benefit from a particular therapeutic product, identify patients at increased risk of severe side effects as a result of the treatment with a particular therapeutic product as well as achieve improved safety or effectiveness.
The companion diagnostics market is expected to experience significant growth during the forecast period owing to growth in demand for advanced therapies, rise in R&D activities to develop low cost & highly efficient drugs, increase in awareness in personalized medicines and surge in demand for cost effective diagnosis are some factors that majorly drive the market growth.
The global companion diagnostics market is segmented based on technology, indication, and region. Based on technology, the market is categorized as immunohistochemistry, polymerase chain reaction (PCR), next Generation Sequencing (NGS), in situ hybridization, and others. On the basis of indication, it is segmented into oncology, neurology, and others. Oncology is further classified into lung cancer, colorectal cancer, breast cancer, blood cancer, and others. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Technology Type
• Immunohistochemistry
• Polymerase chain reaction (PCR)
• Next Generation Sequencing (NGS)
• In situ hybridization
• Others
Indication
• Oncology
o Lung cancer
o Colorectal cancer
o Breast cancer
o Blood cancer
o Others
• Neurology
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Abbott Laboratories Molecular, Inc.
• Agilent (Dako Denmark A/S)
• ARUP Laboratories, Inc.
• BioMerieux SA
• Danaher Corporation (Leica Microsystems)
• Foundation Medicine, Inc.
• Myriad Genetics, Inc.
• Qiagen N.V.
• Roche (Ventana Medical Systems, Inc.)
• Thermo Fisher Scientific (Life Technologies Corporation)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Resonance Health Ltd
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. Key findings
2.2.1. Top investment pockets
2.2.2. Top impacting factors
2.3. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key forces shaping companion diagnostics industry/market
3.2.1. Moderate power of suppliers
3.2.2. High threat of new entrants
3.2.3. Low threat of substitution
3.2.4. Moderate competitive rivalry
3.2.5. Moderate power of buyers
3.3. Parent/ peer market overview
3.5. Market evolution/industry roadmap
3.6. Government regulations for companion diagnostics
3.7. Market dynamics
3.7.1. Drivers
3.7.1.1. Increased popularity of personalized medicine
3.7.1.2. Increase in cases of adverse drug reactions (ADRs)
3.7.1.3. Surge in healthcare expenditure worldwide
3.7.1.4. Technological advancements in diagnostic techniques
3.7.2. Restraints
3.7.2.1. Unfavorable reimbursement policies in some countries
3.7.3. Opportunities
3.7.3.1. Growth opportunities in emerging markets
3.7.3.2. Increase in incidence of cancer across the globe
3.7.4. Impact analysis
CHAPTER 4: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
4.1. Overview
4.1.1. Market size and forecast
4.2. Immunohistochemistry
4.2.1. Market size and forecast, by region
4.2.2. Market analysis, by country
4.3. Polymerase chain reaction (PCR)
4.3.1. Market size and forecast, by region
4.3.2. Market analysis, by country
4.4. Next generation sequencing (NGS)
4.4.1. Market size and forecast, by region
4.4.2. Market analysis, by country
4.5. In situ hybridization
4.5.1. Market size and forecast, by region
4.5.2. Market analysis, by country
4.6. Others
4.6.1. Market size and forecast, by region
4.6.2. Market analysis, by country
CHAPTER 5: COMPANION DIAGNOSTICS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oncology
5.2.1. Key market trends and opportunities
5.2.2. Market size and forecast, by type
5.2.2.1. Lung cancer
5.2.2.1.1. Market size and forecast
5.2.2.2. Colorectal cancer
5.2.2.2.1. Market size and forecast
5.2.2.3. Breast cancer
5.2.2.3.1. Market size and forecast
5.2.2.4. Blood cancer
5.2.2.4.1. Market size and forecast
5.2.2.5. Others
5.2.2.5.1. Market size and forecast
5.2.3. Market size and forecast
5.2.4. Market analysis, by country
5.3. Neurology
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
CHAPTER 6: COMPANION DIAGNOSTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. companion diagnostics market, by technology
6.2.2.1.2. U.S. companion diagnostics market, by indication
6.2.2.2. Canada
6.2.2.2.1. Canada companion diagnostics market, by technology
6.2.2.2.2. Canada companion diagnostics market, by indication
6.2.2.3. Mexico
6.2.2.3.1. Mexico companion diagnostics market, by technology
6.2.2.3.2. Mexico companion diagnostics market, by indication
6.2.3. North America market size and forecast, by technology
6.2.4. North America Market size and forecast, by indication
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany companion diagnostics market, by technology
6.3.2.1.2. Germany companion diagnostics market, by indication
6.3.2.2. France
6.3.2.2.1. France companion diagnostics market, by technology
6.3.2.2.2. France companion diagnostics market, by indication
6.3.2.3. UK
6.3.2.3.1. UK companion diagnostics market, by technology
6.3.2.3.2. UK companion diagnostics market, by indication
6.3.2.4. Rest of Europe
6.3.2.4.1. Rest of Europe companion diagnostics market, by technology
6.3.2.4.2. Rest of Europe companion diagnostics market, by indication
6.3.3. Europe market size and forecast, by technology
6.3.4. Europe Market size and forecast, by indication
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan companion diagnostics market, by technology
6.4.2.1.2. Japan companion diagnostics market, by indication
6.4.2.2. China
6.4.2.2.1. China companion diagnostics market, by technology
6.4.2.2.2. China companion diagnostics market, by indication
6.4.2.3. Australia
6.4.2.3.1. Australia companion diagnostics market, by technology
6.4.2.3.2. Australia companion diagnostics market, by indication
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific companion diagnostics market, by technology
6.4.2.4.2. Rest of Asia-Pacific companion diagnostics market, by indication
6.4.3. Asia-Pacific market size and forecast, by technology
6.4.4. Asia-Pacific Market size and forecast, by indication
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil companion diagnostics market, by technology
6.5.2.1.2. Brazil companion diagnostics market, by indication
6.5.2.2. South Africa
6.5.2.2.1. South Africa companion diagnostics market, by technology
6.5.2.2.2. South Africa companion diagnostics market, by indication
6.5.2.3. Rest of LAMEA
6.5.2.3.1. Rest of LAMEA companion diagnostics market, by technology
6.5.2.3.2. Rest of LAMEA companion diagnostics market, by indication
6.5.3. LAMEA market size and forecast, by technology
6.5.4. LAMEA Market size and forecast, by indication
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.1.1. Market player positioning, 2018
7.2. Top winning strategies
7.3. Competitive dashboard
7.4. Competitive heatmap
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories Molecular, Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Agilent (Dako Denmark A/S)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. ARUP Laboratories, Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Service portfolio
8.4. BioMerieux
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Danaher Corporation (Leica Microsystems)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Foundation Medicine, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Service portfolio
8.6.5. Key strategic moves and developments
8.7. Myriad Genetics, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Roche (Ventana Medical Systems, Inc)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Thermo Fisher Scientific (Life Technologies Corporation)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. QIAGEN N.V.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
TABLE 01. GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026 ($MILLION)
TABLE 02. IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. POLYMERASE CHAIN REACTION MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. NEXT GENERATION SEQUENCING MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. IN SITU HYBRIDIZATION MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026 ($MILLION)
TABLE 08. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 09. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. COMPANION DIAGNOSTICS FOR NEUROLOGY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. COMPANION DIAGNOSTICS FOR OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12. COMPANION DIAGNOSTICS MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 13. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14. U.S. COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 15. U.S. COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 16. CANADA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 17. CANADA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 18. MEXICO COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 19. MEXICO COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 20. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 21. NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 22. EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 23. GERMONY COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 24. GERMANY COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 25. FRANCE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 26. FRANCE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 27. UK COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 28. UK COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 29. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 30. REST OF EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 31. EUROPE COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 32. EUROPE COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 33. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 34. JAPAN COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 35. JAPAN COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 36. CHINA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 37. CHINA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 38. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 39. AUSTRALIA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 40. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 41. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 42. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 43. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 44. LAMEA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 45. BRAZIL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 46. BRAZIL COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 47. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 48. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 49. REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 50. REST OF LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 51. LAMEA COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018–2026
TABLE 52. LAMEA COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2018–2026
TABLE 53. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 54. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 55. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 56. AGILENT: COMPANY SNAPSHOT
TABLE 57. AGILENT: OPERATING SEGMENTS
TABLE 58. AGILENT: PRODUCT PORTFOLIO
TABLE 59. ARUP LABORATORIES: COMPANY SNAPSHOT
TABLE 60. ARUP LABORATORIES: SERVICE PORTFOLIO
TABLE 61. BIOMERIEUX: COMPANY SNAPSHOT
TABLE 62. BIOMERIEUX: OPERATING SEGMENTS
TABLE 63. BIOMERIEUX: PRODUCT PORTFOLIO
TABLE 64. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 65. DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 66. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 67. FOUNDATION MEDICINE: COMPANY SNAPSHOT
TABLE 68. FOUNDATION MEDICINE: SERVICE PORTFOLIO
TABLE 69. MYRIAD GENETICS, INC: COMPANY SNAPSHOT
TABLE 70. MYRIAD GENETICS, INC: OPERATING SEGMENTS
TABLE 71. MYRIAD GENETICS, INC: PRODUCT PORTFOLIO
TABLE 72. ROCHE: COMPANY SNAPSHOT
TABLE 73. ROCHE: OPERATING SEGMENTS
TABLE 74. ROCHE: PRODUCT PORTFOLIO
TABLE 75. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 76. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 77. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 78. QIAGEN N.V: COMPANY SNAPSHOT
TABLE 79. QIAGEN N.V: OPERATING SEGMENTS
TABLE 80. QIAGEN N.V: PRODUCT PORTFOLIO
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
